An interventional study of Serratus plane block (continuous or single-shot) in Rib Fractures and Spirometry, sponsored by Niguarda Hospital. Not yet recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Niguarda Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In patients admitted following a trauma, the incidence of multiple rib fractures is reported to be 9,7%, and this can be even higher in high energy trauma like motor vehicle accidents (1). Pain deriving from rib fractures cause the patient to breath shallow in order to limit discomfort and this bring about negative consequences: shallow breathing and inability to clear secretions may cause pulmonary atelectasis eventually evolving to pneumonia. Given the aforementioned concerns, it is easy to understand why, in a context like this, control of chest pain become crucial. The best way to achieve adequate pain control have not yet been established: the aim of this study is to investigate on this clinical dilemma. In this study, 72 people with at least two monolateral rib fractures are going to be randomized into three groups: 1) standard treatment alone (intravenous analgesia: acetaminophen + morphine PCA); 2) continuous serratus plane block + standard treatment; 3) single-shot serratus plane block + standard treatment. The variables that are going to be recorded are the following: pain through the NRS scale, FEV1 and FVC through spirometry and finally an arterious gas analysis. Recording are going to be repeated at 72h after admission. The primary endpoint is to evaluate if the continuous serratus plane block is able to improve the FEV1/FVC compared to single shot or standard treatment alone. Secondary endpoints will be: the effect of continuous block on 1) resting and incident pain; 2) opioid consumption; 3) blood gas analysis parameters; 4) pulmonary complications at 1 month; 5) length of stay
126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.
This study's planned enrollment of 72 is above the median of 60 across 92 interventional studies indexed under Rib Fractures.
Browse Rib Fractures studies →Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Procedure: Serratus plane block (continuous or single-shot)
Procedure: Serratus plane block (continuous or single-shot)
Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
FEV1 (% of the predicted value)
Any statistically significant difference between the two treatment groups and the control group will be measured. FEV1 is expected to be respectively 80±15% of the predicted value in the treatment groups and 64±15% of the predicted value in the control group
Time frame: 72 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jun 2027; primary completion for Dec 2027, 6 months later.
Of 41 non-industry interventional studies with no phase under Rib Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 6 months is below that.
Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 15 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jun 2026 → Jun 2027, primary completion Dec 2026 → Dec 2027 and completion May 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Niguarda Hospital